Melatonin and the Regulation of Sleep and Circadian Rhythms

Guardiola‐Lemaître, B.; Quera-Salva, Maria Antonia

doi:10.1016/b978-1-4160-6645-3.00036-0

Cited by 15 publications

(9 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Melatonin levels in the pineal gland are low during the daytime and increase after the onset of darkness (9-10 pm), reaching peak levels when it is darkest (3-5 am). 13,14 The two-process model of sleep regulation, which has been used to explain 24-hour sleep regulation in humans, includes the following: Process S, which is entirely determined by the temporal sequence of behavioral states; and Process C, which is totally controlled by the circadian pacemaker, irrespective of behavioral state. 15 In the elderly, reduced homeostatic sleep pressure decreases the amount of slow-wave sleep.…”

Section: Physiology Of Sleep and Age-related Changes In Sleepmentioning

confidence: 99%

Sleep disorders in the elderly: Diagnosis and management

Suzuki

Miyamoto

Hirata

2017

J of Gen and Family Med

182

120

View full text Add to dashboard Cite

Compared with younger people, elderly people show age‐related sleep changes, including an advanced sleep phase and decreased slow‐wave sleep, which result in fragmented sleep and early awakening. Multiple etiologies contribute to insomnia in the elderly, consistent with the observation that elderly people are likely to have comorbid conditions and medications. When elderly individuals complain of insomnia, it is important to assess treatable medical conditions and medication use that may be responsible for the insomnia before the use of hypnotics is initiated. Also, screening for primary sleep disorders, such as sleep apnea syndrome, restless legs syndrome and rapid eye movement sleep behavior disorder, is essential. We review sleep disorders commonly observed in the elderly and describe their diagnosis and management.

show abstract

Section: Physiology Of Sleep and Age-related Changes In Sleepmentioning

confidence: 99%

Sleep disorders in the elderly: Diagnosis and management

Suzuki

Miyamoto

Hirata

2017

J of Gen and Family Med

182

120

View full text Add to dashboard Cite

show abstract

“…In clinical practice exogenous melatonin (0.3-5 mg) may be administered in the evening to achieve a phase advance (Fuardiola-Lemaître and Quera-Salva, 2011). The phase delaying effects of melatonin administered in the morning have been more questioned (Wirz-Justice et al, 2002;Fuardiola-Lemaître and Quera-Salva, 2011).…”

Section: Entrainment By Melatoninmentioning

confidence: 99%

Prevalence and correlates of delayed sleep phase in high school students

Saxvig¹,

Pallesen²,

Wilhelmsen-Langeland³

et al. 2012

Sleep Medicine

190

138

View full text Add to dashboard Cite

show abstract

“…Therefore, an innovative approach to improve the treatment of depression in patients with abnormal circadian rhythmicity may include the administration of circadian phase‐shifting agents. The goal of such treatment is not only to restore sleep–wake patterns (Guardiola‐Lemaitre and Quera‐Salva, ), but also to resynchronize the circadian system and its link with the external environment. This way of thinking lead to the discovery of agomelatine (Adam et al ., ; Yous et al ., ), a compound that combines melatonin receptor (see Alexander et al ., ) agonism with 5‐HT 2C receptor antagonism (Delagrange and Guardiola‐Lemaitre, ).…”

Section: Introductionmentioning

confidence: 99%

Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties

Guardiola‐Lemaître

Bodinat

Delagrange

et al. 2014

British J Pharmacology

138

106

View full text Add to dashboard Cite

Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. The recent demonstration of the existence of heteromeric complexes of MT1 and MT2 with 5-HT2C receptors at the cellular level may explain how these two properties of agomelatine translate into a synergistic action that, for example, leads to increases in hippocampal proliferation, maturation and survival through modulation of multiple cellular pathways (increase in trophic factors, synaptic remodelling, glutamate signalling) and key targets (early genes, kinases). The present review focuses on the pharmacological properties of this novel antidepressant. Its mechanism of action, strikingly different from that of conventional classes of antidepressants, opens perspectives towards a better understanding of the physiopathological bases underlying depression.

show abstract

Melatonin and the Regulation of Sleep and Circadian Rhythms

Cited by 15 publications

References 146 publications

Sleep disorders in the elderly: Diagnosis and management

Sleep disorders in the elderly: Diagnosis and management

Prevalence and correlates of delayed sleep phase in high school students

Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties

Contact Info

Product

Resources

About